Goucher College in Baltimore, Maryland and a law degree from Boston University and is a member of the Massachusetts and North Carolina Bars. An active member of the university technology-transfer community, she has chaired and participated in numerous workshops and seminars on technology transfer practice and intellectual property law, and is a past president of the Association of University Technology Managers. For the past five years, Ms. Hersey has served as a consultant to the Association of Research Libraries (ARL) on intellectual property and other legal issues confronting university libraries. She worked with the ARL to develop both a basic and advanced course for librarians covering copyright and the licensing of electronic resources. She participates as an instructor for both courses several times throughout the year.

Steven H.Holtzman is the President and Chief Executive Officer of Infinity Pharmaceuticals, Inc. Previously, he was the Chief Business Officer of Millennium Pharmaceuticals, Inc. in which role his responsibilities included licensing, intellectual property and corporate law, government relations, and public policy. Prior to joining Millennium, from 1986 to 1994, Mr. Holtzman was a founder and the first employee of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. In the early 1980s, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation’s first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970s, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. In 1995, Mr. Holtzman was a founding Co-Chair and is a current member of the Biotechnology Industry Organization (BIO) Bioethics Committee. In 1998, he served as a member of the Working Group of the Advisory Committee to the Director of the NIH on Access to Research Tools. In 1996, he was appointed by President Clinton as